JG TERMINAL T1: Outpick Strategy
JG ETF JG ETF
← Back to Screener

PTGX Protagonist Therapeutics, Inc. Common Stock

Healthcare · Biotechnology

MKTCAP: $7B

2.4
Sell

COMPOSITE: 35.3

PTGX scores poorly with a 2.4/5.0 Quant Rating (Sell). Strongest factors: Momentum (B+, 73th %ile). Weakest factors: Profitability (C, 34th %ile), Analyst Revisions (D+, 14th %ile). Analyst estimates are trending down, which weighs heavily against this stock (30% of score).

Valuation

C+ 40%

Growth

C+ 38%

Profitability

C 34%

Momentum

B+ 73%

Revisions

D+ 14%

Rating History

Valuation Metrics

Metric Value Percentile
Pe Ttm -42.60
90%
Peg 0.29
32%
Ev Ebitda Ttm -42.43
92%
Ev Sales Ttm 118.10
6%
Price To Book 9.03
17%
Price To Sales Ttm 120.66
6%

Growth Metrics

Metric Value Percentile
Rev Growth Yoy -0.89
2%
Rev Growth Fwd 10.15
98%
Eps Growth Yoy -1.46
10%
Eps Growth Fwd 3.15
97%
Ebitda Growth Yoy -1.46
7%
Ocf Growth Yoy -0.69
11%

Profitability Metrics

Metric Value Percentile
Gross Margin 0.97
92%
Operating Margin -3.44
11%
Net Margin -2.83
12%
Ebitda Margin -2.78
11%
Roa -0.19
38%
Roic -0.25
36%
Fcf Margin 0.97
46%
Asset Turnover 0.07
29%

Momentum Metrics

Metric Value Percentile
Return 1M 3.80
74%
Return 3M 3.80
75%
Return 6M 3.80
72%
Return 12M 3.80
71%
Momentum Accel 42.0

Revisions Detail

Metric Value Percentile
Eps Up 90D 1
Eps Down 90D 0
Rev Up 90D 0
Rev Down 90D 0
Revision Score -0.8194660255564719
Percentile 13.6